<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="3-part\PMC7108492\results\search\disease\results.xml">
  <result pre="priorities for funding and coordination in the coming years. CEPI" exact="chikungunya" post="epidemic infectious diseases epidemic preparedness global health research and"/>
  <result pre="studies of candidate vaccines, before the trials of the vesicular" exact="stomatitis" post="virus–Ebola virus vaccine (Merck, Kenilworth, New Jersey) in Guinea"/>
  <result pre="of R&amp;amp;D into biodefense-related Ebola countermeasures and because the vesicular" exact="stomatitis" post="virus–Ebola virus vaccine manufactured by Merck demonstrated effectiveness in"/>
  <result pre="absence of product stockpiles. Although the trials assessing the vesicular" exact="stomatitis" post="virus–Ebola virus vaccine did not commence until late in"/>
  <result pre="virus disease; Lassa fever; Middle East respiratory syndrome–related coronavirus (MERS-CoV);" exact="severe acute respiratory syndrome;" post="Nipah virus disease; Rift Valley fever; severe fever with"/>
  <result pre="syndrome; Nipah virus disease; Rift Valley fever; severe fever with" exact="thrombocytopenia" post="syndrome; and Zika virus. The revised list, as of"/>
  <result pre="Marburg virus disease (priority list); Lassa fever (priority list); MERS-CoV," exact="severe acute respiratory syndrome" post="(priority list); Nipah and henipaviral diseases (priority list); Rift"/>
  <result pre="(priority list); arenaviral hemorrhagic fevers other than Lassa fever (watchlist);" exact="chikungunya" post="(watchlist); highly pathogenic coronaviral diseases other than MERS and"/>
  <result pre="chikungunya (watchlist); highly pathogenic coronaviral diseases other than MERS and" exact="severe acute respiratory syndrome" post="(watchlist); emergent nonpolio enteroviruses, including EV71, D68 (watchlist); and"/>
  <result pre="nonpolio enteroviruses, including EV71, D68 (watchlist); and severe fever with" exact="thrombocytopenia" post="syndrome (watchlist). Earlier that year, inspired by a call"/>
  <result pre="2019, CEPI expanded its list of priority pathogens to include" exact="chikungunya" post="and Rift Valley fever. According to initial estimates, a"/>
  <result pre="develop a vaccine against Lassa virus and MERS-CoV, using a" exact="measles" post="vector technology March 2018 Inovio $56 million to develop"/>
  <result pre="develop a vaccine against Lassa virus, using a replication-competent vesicular" exact="stomatitis" post="virus vector technology May 2018 Profectus Biosciences, Emergent, and"/>
  <result pre="tailored vaccine production against multiple viral pathogens (including H1N1 influenza," exact="rabies" post="virus, and Marburg virus) December 2019 University of Queensland"/>
  <result pre="targeted and rapid vaccine production against multiple viral pathogens (including" exact="influenza" post="virus, MERS-CoV, and respiratory syncytial virus) December 2019 University"/>
  <result pre="by inserting the Nipah-virus G gene (Malaysia strain) into a" exact="measles" post="vector (Edmonston B strain) February 2019 CureVac $34 million"/>
  <result pre="vaccine candidate that can target known pathogens (including Lassa fever," exact="yellow fever," post="and rabies); and prepare for rapid response to unknown"/>
  <result pre="2019 Themis Bioscience $21 million to advance a vaccine against" exact="chikungunya" post="virus through phase 3 clinical trials and to accelerate"/>
  <result pre="so at-risk populations have access to the vaccine, using a" exact="measles" post="vector technology June 2019 Wageningen Bioveterinary Research $12.5 million"/>
  <result pre="and late-stage clinical development of a single-dose, live-attenuated vaccine against" exact="chikungunya" post="virus July 2019 Public Health Vaccines $43.6 million to"/>
  <result pre="a vaccine against the Nipah virus, using a recombinant vesicular" exact="stomatitis" post="virus technology August 2019 Abbreviations: MERS-CoV, Middle East respiratory"/>
  <result pre="an outbreak, as well as late-stage clinical development of advanced" exact="chikungunya" post="vaccines to accelerate regulatory approval so at-risk populations have"/>
  <result pre="Lassa fever, 1 against respiratory syncytial virus, and 1 against" exact="yellow fever." post="CEPI’s R&amp;amp;D portfolio includes several vaccines based on attenuated"/>
  <result pre="tested in the clinic, such as a measles-vector–based vaccine against" exact="chikungunya" post="developed by Themis Bioscience (Vienna, Austria) (22); an attenuated"/>
  <result pre="Themis Bioscience (Vienna, Austria) (22); an attenuated virus vaccine against" exact="chikungunya" post="developed by Valneva (Vienna, Austria) (23); a DNA-based vaccine"/>
  <result pre="quantity of antibody would be required to induce protection against" exact="chikungunya" post="could make the identification of situations that would allow"/>
  <result pre="Republic of Congo. Thankfully, thousands of doses of the vesicular" exact="stomatitis" post="virus–Ebola virus vaccine have already been manufactured and the"/>
  <result pre="candidates are about to initiate late-stage preclinical development; and 2" exact="chikungunya" post="vaccine candidates are about to resume late-stage clinical development"/>
  <result pre="fever, MERS-CoV, influenza, rabies, respiratory syncytial virus, Marburg virus, and" exact="yellow fever." post="CEPI will continue to enhance epidemic preparedness through targeted"/>
  <result pre="Austria. Study to Assess the safety and immunogenicity of a" exact="chikungunya" post="virus vaccine candidate (VLA1553) in healthy volunteers. https://clinicaltrials.gov/ct2/show/NCT03382964. Updated"/>
 </snippets>
</snippetsTree>
